Amphastar Pharmaceuticals, Inc.
No enriched coverage for $AMPH in the last 7 days.
No SEC Form 4 filings for $AMPH in the last 30 days.
Amphastar Pharmaceuticals Inc. reported first-quarter earnings of $6.4 million, or 14 cents per share, which adjusted to 42 cents per share. These results fell below Wall Street's expectations of 70 cents per share from analysts surveyed by Zacks Investment Research. The company's revenue for the period was $171.2 million, and its shares have declined 10% year-to-date.
Amphastar Pharmaceuticals provided updates on its growth drivers and pipeline at the Needham conference. The company expects Baqsimi sales to hit $175 million this year, triggering a significant milestone payment, despite some pricing pressure. Primatene Mist is projected for high single to low double-digit growth, while Amphastar also plans for new launches, including AMP-007 in early Q2 and key diabetes biosimilars in 2027.
Image source: The Motley Fool.Saturday, Nov. 8, 2025 at 12:16 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
